Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisinicline for Vaping Cessation (ORCA-V2)
NCT07392125Phase 3Not yet recruiting
- Sponsor
- Achieve Life Sciences
- Start
- May 2026
- Primary completion
- Nov 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of cytisinicline in nicotine dependence, sponsored by Achieve Life Sciences. Planned start May 2026; status: not yet recruiting.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT07392125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392125.